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The metabolic syndrome (MS), formally known as syndrome X, is a clustering of several
risk factors such as obesity, hypertension, insulin resistance, and dislypidemia which
could lead to the development of diabetes and cardiovascular diseases (CVD). The
frequent changes in the definition and diagnostic criteria of MS are indications of the
controversy and the challenges surrounding the understanding of this syndrome among
researchers. Obesity and insulin resistance are leading risk factors of MS. Moreover,
obesity and hypertension are closely associated to the increase and aggravation of
oxidative stress. The recommended treatment of MS frequently involves change of
lifestyles to prevent weight gain. MS is not only an important screening tool for the
identification of individuals at high risk of CVD and diabetes but also an indicator
of suitable treatment. As sympathetic disturbances and oxidative stress are often
associated with obesity and hypertension, the present review summarizes the role of
sympathetic nervous system and oxidative stress in the MS.
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Introduction
Cardiovascular diseases (CVD) are major causes of morbidity and mortality worldwide (WHO,
2013). The risk factors of CVD include hypertension, hypercholesterolemia, diabetes, genetic
predisposition, obesity, sedentary lifestyle, and smoking (WHO, 2013). Unlike other risk factors,
smoking and sedentary lifestyle are preventable. The risk factors that cannot be prevented often
occur together. The clustering of these risk factors has been studied extensively (Kagota et al., 2010;
Salazar et al., 2011; Gyawali et al., 2015). Reaven (1988) observed that insulin-resistant subjects
often manifest obesity, high level of low-density lipoprotein (LDL)-cholesterol, low level of high-
density lipoprotein (HDL)-cholesterol, fasting hyperglycemia and increased arterial blood pressure.
These manifestations with multiple risk factors to the development of CVD were called Syndrome
X (Reaven, 1988; Grundy et al., 2004). Later, the Syndrome X was renamed as Metabolic Syndrome
(MS). In other words, MS is a clustering of several metabolic changes that affect the organism and
often result in CVD.
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The prevalence of CVD has increased since the advent of
industrial revolution especially in western societies (Gottlieb
et al., 2008). The less active lifestyle being promoted by modern
transportation system, exclusion of manual jobs with high scale
mechanized production and widespread consumption of fat rich
food has contributed greatly to the increasing cases of obesity
and MS. The consumption of industrial products which are
also rich in sugar and salt elicits harmful effects on insulin
resistance (Vidonho et al., 2004; Salazar et al., 2011) and blood
pressure (Vidonho et al., 2004; He et al., 2008; Moreira et al.,
2014). According to Stoian and Stoica (2014), MS patients exhibit
lower concentrations of serum phosphate and magnesium as
compared to subjects who did not meet the criteria for the
diagnosis of this syndrome. Phosphate and magnesium are
crucial to carbohydrate metabolism, thus, it is not surprising to
suggest that lower level of these ions in MS patients can lead
to a decrease in peripheral utilization of glucose as well as the
development or aggravation of insulin resistance (Stoian and
Stoica, 2014).
Some studies have demonstrated that oxidative and
inflammatory stress play an important role in the initiation
and progression of CVD (Toshima et al., 2000; Libby et al., 2002).
It has been established that obesity could lead to an increase in
the circulating markers of oxidative stress and inflammation
(Festa et al., 2000; Keaney et al., 2003). As obesity is an important
risk factor of MS, the establishment of a definitive relationship
between inflammation and oxidative stress has attracted a lot of
interest. However, there are still dearth of information in this
regard.
In order to unravel the pathophysiology of MS, several
definitions and diagnostic parameters have been proposed. The
WorldHealthOrganization (WHO) definedMS as a group of risk
factors of CVD and diabetes (Alberti and Zimmet, 1998; Grundy
et al., 2004). WHO considered insulin resistance as the primary
cause of MS (Grundy et al., 2004). This diagnostic consideration
predicts diabetes in MS. However, the need of a specific test for
insulin resistance makes MS diagnostic criteria by WHO less
accessible (Grundy et al., 2004). According to WHO, the insulin
resistance can be identified through one of the following factors:
(i) type 2 diabetes; (ii) impaired fasting glucose; or (iii) impaired
glucose intolerance. Besides the insulin resistance, at least two
other risk factors are required to diagnose the syndrome (Alberti
and Zimmet, 1998; Grundy et al., 2004). Some of the diagnostic
criteria for MS are shown in Table 1.
TABLE 1 | WHO—Diagnostic criteria for metabolic syndrome.
Factor Limit levels
High blood pressure ≥140/≥90mmHg or antihypertensive medication
Plasma triglycerides ≥150 mg/dL (1.7mM)
HDL cholesterol
Men <35 mg/dL (0.9mM)
Women <39 mg/dL (1.0mM)
Body mass index >30 kg/m2
Urinary albumin excretion rate ≥20µg/min
Major Components of Metabolic Syndrome
Abdominal Obesity
Obesity is defined by WHO as an abnormal or excessive fat
accumulation that causes health problems (Mendis et al., 2015).
The body mass index (BMI) is a parameter being are used to
classify overweight and obesity in adults. BMI is calculated using
the formula weight/height2 (kg/m2). WHO defines a BMI greater
than or equal to 30 kg/m2 as obesity. Although the prevalence
of obesity has been doubled worldwide since 1980, it is still a
preventable disease. Nowadays, obesity kills more people than
underweight globally. In 2014, it was reported that 39% of the
adults (≥18 years) were overweight and 13% obese. About 42
million of people under 5 years of age were overweight in 2013
(Mendis et al., 2015).
Basically, obesity is caused by the imbalance between
the calories consumed and calories expended. The higher
consumption of calories as compared to the calories expended
has being associated with weight gain. The accumulation of
adipose tissue in the abdominal region causes abdominal obesity.
Several studies have demonstrated that abdominal obesity which
can be measured by the waist circumference has a strong
correlation with the development of CVD (Ferreira and Moisés,
2000; Salazar et al., 2011; Traissac et al., 2015).
Considering the strong relationship among obesity, MS
and cardiovascular risk factors, it is important to unravel
the autonomic disturbances in obesity. Though the autonomic
imbalance is not homogeneous in obesity, some studies
demonstrated sympathetic hyperactivity in most part of obese
individuals (Lopes and Egan, 2006). In the obese individuals, the
sympathetic tone is increased in target organs such as kidney,
skeletal muscle and peripheral vessels to elicit hypertension (Esler
et al., 2001; Lopes and Egan, 2006).
Hypertension
Hypertension is, by definition, a sustained increase in the
arterial blood pressure (WHO, 2013). Nowadays, hypertension
and its complications is one of the major cause of death
worldwide. Factors such as increase in the sympathetic activity
and dysregulation in sodium homeostasis could cause an
increase in the arterial blood pressure. Although the pathogenesis
of hypertension is still unclear, salt consumption has been
implicated as one of the important causes of this disease (da Costa
Lima et al., 1997; Ito et al., 1999; Contreras et al., 2000; Sacks
et al., 2001; Rodriguez-Iturbe and Vaziri, 2007; He et al., 2008;
Moreira et al., 2014). In addition, sedentary lifestyle, obesity and
smoking are other factors that contribute to increase in blood
pressure (Filho et al., 2008). The long-term increase in arterial
blood pressure often affects some organs, like heart and kidneys.
The higher the blood pressure, the greater is the resistance needed
by heart to function. A higher blood pressure could lead to
an increase in the frequency and contractile force. In the long-
term, this changes in blood pressure could compromise cardiac
function (Zile, 2002; Cingolani et al., 2003; Chen-Izu et al., 2007).
According to WHO, hypertension is a systolic blood pressure
equal to or above 140mmHg and/or diastolic blood pressure
equal to or above 90mmHg (WHO, 2013).
Frontiers in Physiology | www.frontiersin.org 2 August 2015 | Volume 6 | Article 234
Moreira et al. Sympathetic nervous system and metabolic syndrome
Endothelial dysfunction has been identified in hypertension.
Endothelium is a cellular layer on the vascular wall that
controls the traffic of small and large molecules, and maintains
the integrity of vascular wall (Carvalho et al., 2001). The
endothelium controls the expansion and contraction of blood
vessels by producing local mediators that are involved in
vasodilation (endothelium-derived relaxing factors–EDRFs)
or vasoconstrictor (endothelium-derived constriction factors–
EDCFs) in response to changes in blood flow or vasoactive
agents (Carvalho et al., 2001). The endothelium has multiple
and important roles in physiological events: (i) it acts as
hemodynamic sensor by receiving and transmitting signals from
the extracellular matrix and cells; (ii) it produces mediators that
interfere with growth, activity, migration and cell death; and (iii)
it preserves the adaptive changes to circulatory requirements
(Carvalho et al., 2001).
The principal EDRFs are nitric oxide (NO), the endothelium-
derived hyperpolarizing factor (EDHF) and prostacyclin (PGI2).
Angiotensin II (Ang II) and superoxide or reactive oxygen
species (ROS) are among the main EDCFs (Kang, 2014). In
pathophysiological situations, such as hypertension, an increase
of EDCFs occurs. In this condition, study has shown an
increase in the release of endothelial derived contractile factors
cyclooxygenase (e.g., PGH 2) in response to acetylcholine
and angiotensin II in aorta and mesenteric arteries of SHR
(Côrtes et al., 1996). This result suggests endothelial dysfunction
in hypertension. Under physiological conditions, there is a
balance between the release, and production of the most
important relaxing and contractile factors. This balance could be
changed by attenuation of vasodilatory effect of endothelium. An
apparent decrease in vascular endothelial-dependent relaxation
is called endothelial dysfunction (Carvalho et al., 2001). The
mechanisms involved in endothelial dysfunction as found in
hypertension is multifactorial. Preclinical studies have shown
an increase in the basal activity of nitric oxide synthase
(NOS) and a decrease in the expression and activity of
soluble guanylyl cyclase in smooth muscle of spontaneously
hypertensive rats (Bauersachs et al., 1998; Kojda et al., 1998).
On the other hand, in Dahl rats with salt-sensitive hypertension,
there is a decrease in the responsiveness of vascular smooth
muscle cells due to a decrease in the eNOS activity and
NO production (Luscher and Vanhoutte, 1986; Hayakawa
and Raij, 1998). EDHF has been described as one of the
principal mediators of endothelium-dependent vasorelaxation
in normotensive animals. The contribution of EDHF-mediated
relaxation appears significantly greater in small resistance vessels
than in large conduit vessels (Félétou and Vanhoutte, 2006).
A reduction in the release of EDHF may lead to endothelial
dysfunction and subsequently arterial hypertension (Fujii et al.,
1992).
The oxygen and oxidative reactions in the body are vital for
energy supply and defense against invaders. Under physiological
conditions, the enzyme superoxide dismutase is responsible for
preventing the formation of reactive species of oxygen such as
peroxynitrite (ONOO-) which has a detrimental effects in the
body (McIntyre et al., 1999). However, under oxidative stress
condition as in MS, a large amount of O2 reacts with NO to form
(ONOO–). This reaction could lead to a significant reduction in
the bioavailability of endothelial NO.
Nitric oxide are highly relevant in endothelial dysfunction
because in this pathology, production may be reduced due
to changes in NOS3 (Nitro oxide synthase type 3) protein as
observed in animalmodels of cardiovascular disease such as SHR,
DOCA, diabetic rats (Hink et al., 2001; Sullivan et al., 2002). The
reduction in the bioavailability of NO is considered as part of the
mechanism for endothelial dysfunction in oxidative stress. NO
could reacts with O2 to cause vasoconstriction, vascular damage
and lipid peroxidation (Virdis et al., 2002).
In summary, endothelial dysfunction is characterized by
an imbalance in the release of vasoconstrictors and the
endothelium-dependent relaxants. Hence, increases in EDCFs
are common in pathophysiological condition like hypertension.
Insulin Resistance
The insulin-resistance occurs when the body cells become less
sensitive and resistant to insulin. Insulin, an hormone which
facilitate glucose absorption, is produced in the beta cells of
the pancreas (The IDF consensus worldwide definition of the
MS: IDF, 2006). Once the glucose cannot be absorbed by the
cells, it remains in the blood and subsequently triggers off the
production of more insulin (hyperinsulinaemia reflex). The over
production of insulin often wears off beta cells and diminishes
its capacity to produce insulin. This condition generally leads to
hyperglycaemia and type 2 diabetes (WHO and IDF, 2006; The
IDF consensus worldwide definition of the MS: IDF, 2006). The
insulin-resistance promotes damage to several insulin-sensitive
organs such as liver and kidneys. The hyperinsulinaemia reflex
increases the release of triglycerides by liver into the bloodstream
and subsequent decrease in the level of HDL cholesterol, increase
in the level of small and dense particles of LDL cholesterol
(Reaven, 1988, 2003; Yoon et al., 2014). The hyperinsulinaemia
reflex can contribute to the pathophysiology of the essential
hypertension through an increase in renal water absorption
and/or increase in the sympathetic activity (Reaven, 2003; Yoon
et al., 2014). The insulin resistance is a major risk factor of type
2 diabetes and atherosclerotic complications such as coronary
artery disease, stroke and peripheral arterial disease (Yoon et al.,
2014).
Dislypidemia
The dislypidemia is considered as an unbalance serum level
of LDL (which increases) and HDL cholesterol particles
(which decreases) (Reaven, 1988). As defined by Kaur (2014),
dyslipidemia is characterized by spectrum of qualitative lipid
abnormalities that reflect perturbations in the structure,
metabolism, and biological activities of both atherogenic
lipoproteins and antiatherogenic HDL cholesterol. Dislypidemia
is frequently associated to insulin resistance. As mentioned
above, the hyperinsulinaemia reflex, caused by the insulin
resistance, promotes increase in the hepatic release of
triglycerides to the blood. This release could decrease the
level of HDL cholesterol and increase the level of small and
denser particles of LDL cholesterol (Reaven, 1988, 2003; Yoon
et al., 2014).
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The increase in serum level of small and denser LDL
cholesterol particles could lead to the accumulation of
triglyceride in the vessels and development of atherosclerosis
among other cardiovascular complications (Reaven, 1988, 2003).
Inflammation and Oxidative Stress in Metabolic
Syndrome
The increase in oxidative stress and inflammatory state are
known to play an important role in the initiation and progression
of CVD (Toshima et al., 2000; Libby et al., 2002). Obesity and
MS have been associated with increased circulating markers of
oxidative stress and inflammation (Festa et al., 2000; Keaney
et al., 2003). However, there are still few information on the
relationship between MS and inflammation/oxidative stress. The
possible link between MS and inflammation is resistance to
insulin (RI) (Volp et al., 2008). A defective insulin action in
target tissues (muscle, liver, and adipose tissue) could increase
chronic inflammation (Dandona et al., 2007). T cells elaborate
inflammatory and anti-inflammatory properties of cytokines by
stimulating macrophages, endothelial cells and smooth muscle
cells (Volp et al., 2008). The key inflammatory cytokines
markers include interleukin-6 (IL-6), tumor necrosis factor-
α (TNF-α), interleukin-8 (IL-8), interleukin-1β (IL-1β), CD40,
CD40L, and C-reactive protein (Kon et al., 2005; Wu and
Wu, 2006). Since the adipocytes cells are the main producers
of cytokines proinflammatory, there is a strong relationship
between increased secretion and higher levels of cytokines in
obese people. This phenomenon increases the risk of developing
MS (Vanhala et al., 2006).
IL-6 is a pro-inflammatory cytokine involved in the
development of hyperinsulinemia and MS. This cytokine
increases lipolysis to release free fatty acids and glycerol while
reducing the expression of insulin receptor substrate-1 (IRS-1)
and GLUT4 in muscle and liver tissues (Francisco et al.,
2006). Though IL-6 is mainly secreted by adipocytes, it is
produced by smooth muscle cells, endothelial cells, monocytes
and macrophages and may contribute to the development of
atherosclerotic lesions through its paracrine, autocrine, and
endocrine effect. Studies have correlated the values of serum IL-6
with the waist circumference (Rexrode et al., 2003). People with
central obesity are at increased risk to develop MS.
The TNF-α is a cytokine with autocrine, paracrine and
endocrine action (Ruan and Lodish, 2003). In obese humans,
there is an inverse correlation between TNF-α and glucose
metabolism (Winkler et al., 2003). Insulin signaling suppression
by the TNF-α reduces the translocation of glucose transporter
(GLUT-4) to the membrane and consequently promotes a
decrease in insulin-mediated glucose uptake by cells. It is also
known that the expression of mRNA and TNF-α secretion are
higher in obese person (Hsueh and Law, 2003).
IL-1β is responsible for increase in the expression of
endothelial adhesion molecules which facilitate the aggregation
of other inflammatory cells in the activated endothelium
(Francisco et al., 2006). IL-1β, together with TNF-α, stimulates
IL-6 production by smooth muscle cells and increases the
expression of macrophages. This process is associated with
the progression of inflammatory and atherosclerosis processes
(Francisco et al., 2006). IL-18 is a proinflammatory cytokine
with pleiotropic action which induces the secretion of the
cytokines IL-6, TNF-α, IL-1β and endothelial adhesionmolecules
(Francisco et al., 2006). This cytokine exerts chemotaxis
of human T cells to promote the recruitment into the
atherosclerotic plaque. It has been proposed that the IL-18
induces the expression of several matrix metalloproteinases,
which may weaken the fibrous cap of injury atherosclerotic
(Hung et al., 2005).
The cytokines CD40 and CD40L are expressed by
macrophages, lymphocytes T, platelets, endothelial cells and
muscle cells flat (Hung et al., 2005). The system CD40/CD40L
exerts various pro-inflammatory and pro-thrombotic effects by:
(i) stimulating the production of endothelial cells free radicals
to antagonize nitric oxide production; (ii) inducing expression
of endothelial cells and smooth muscle adhesion molecules; (iii)
stimulating the expression of proinflammatory cytokines and
chemokines; (iv) inducing tissue factor expression on endothelial
and smooth muscle cells to promote an increase in potential
thrombogenic plate; and (v) participating in the activation of
platelet (Angelico et al., 2006). Data has shown that CD40 which
is expressed on the surface of platelets could activate platelet to
promote thrombus formation (Angelico et al., 2006).
C-Reactive Protein (CRP) is synthesized by the liver and
regulated by cytokines, predominantly IL-6, TNF-α, and IL-1
(Abdellaoui and Al-Khaffaf, 2007). Its levels are increased
during acute inflammatory process. Mild increase in the level
of CRP also occurs in chronic inflammatory condition such as
atherosclerosis. The levels of this protein almost triple in the
presence of peripheral vascular disease risk (Abdellaoui and Al-
Khaffaf, 2007). It has been shown that MS patients have CRP
serum levels significantly higher than people without MS (Bahia
et al., 2006).
Macrophages are a heterogeneous population of immune cells
that have a range of roles in both the induction and resolution
of inflammation (Dey et al., 2015). The pleiotropic responses are
coordinated through distinct programs of macrophage activation
classified as classical (or M1) and alternative (or M2) activation
(Gordon, 2003; Martinez et al., 2008).
It has been shown that the immune response that is activated
during inflammation and obesity-induced insulin resistance has
the same M1 mechanism (Takeda et al., 2003). In classical
activation of macrophages, lipids derived from bacteria bind
to Toll-like receptor 4 (TLR4) and activate signaling pathways
that induce, for example, the release of NF-kB inflammatory
molecules (TNF, IL-6 and 2) (Takeda et al., 2003). In obesity
and inflammation, saturated fatty acids activate TLR4 to promote
inflammatory responses (Shi et al., 2006; Kim et al., 2007; Nguyen
et al., 2007). In fact, acute infusion of lipids into mice potentiates
the insulin resistance in both adipose tissue and skeletal muscle in
a TLR4-dependent manner (Kim et al., 2007). In addition, other
studies have shown that white adipose tissue of obese rats have
mainly macrophages with classically activated—M1 phenotype
(Bouloumié et al., 2005; Ferrante, 2007). Alternatively, during
the resolution of inflammation, the balance of macrophage
activation toward an M2 phenotype occurs in order to promote
clearance of debris and inhibit the production of inflammatory
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mediators to restore tissue homeostasis (Mills et al., 2014).
M2 macrophages produce anti-inflammatory cytokines and
express endocytic receptors. These cells promote the clearance
of apoptotic cells, proliferation and wound healing (Mills et al.,
2014). Together, these data suggest a model in which increased
flux of saturated fatty acids, as seen in obese states stimulates
classical macrophage activation, tissue inflammation, and insulin
resistance.
Although the number of classically activated adipose tissue
macrophages increases with obesity, adipose tissue of lean
animals contains a moderate number of macrophages. The
adipose tissue macrophage of lean mice under non-inflammatory
conditions express high levels of substances encoded by genes
of alternatively activated M2 macrophages that promotes tissue
homeostasis and repair (Hung et al., 2005; Vanhala et al., 2006).
As suggested by Palaniappan et al. (2003), obesity results in a
change in the activation pathway of macrophages.
Van Guilder et al. (2006) evaluated a possible synergistic effect
of MS and obesity on the circulating markers of oxidative stress
and inflammation. In that study, the authors observed that MS
heightens oxidative stress and inflammatory burden in obese
adults, thereby suggesting that MS and obesity have a synergistic
effect on oxidative stress and inflammationmarkers (Van Guilder
et al., 2006). Furthermore, the authors suggested that the
increased oxidative and inflammatory stress may contribute to
risk of coronary heart disease and cerebrovascular disease in
obese adults with MS (Van Guilder et al., 2006).
Several studies have related the adipose tissue to the elevated
markers of oxidative stress and inflammation once the expression
and secretion of such markers increase in proportion to adiposity
(Mohamed-Ali et al., 1998; Bertin et al., 2000; Kern et al., 2001;
Van Guilder et al., 2006). However, as observed by Van Guilder
et al. (2006), the adiposity alone do not seems to be the primary
cause of oxidative stress and inflammation once the markers are
increased only in the obese individuals diagnosed with MS.
In addition, an increase in glucose metabolism has been
implicated in oxidative stress—MS, relation (Furukawa et al.,
2004; Tangvarasittichai, 2015). During the metabolism of glucose
(glycolysis and tricarboxylic acid—TCA cycle), the electron
donors NADH (nicotinamide adenine dinucleotide) and FADH2
(flavin adenine dinucleotide) are generated (Tangvarasittichai,
2015). In the case of over nutrition or obesity, a large amount
of glucose is oxidized in such a way that an increase in the
generation of NADH and FADH2 in the mitocondrial electron
transport chain subsequently result in an increase in superoxide
generation (Tangvarasittichai, 2015). Furthermore, the increase
in free fatty acid and acetyl coenzyme A (CoA) oxidation (due
to the excessive of free fatty acids) in TCA cycle generate
more molecules of NADH and FADH2 to be oxidized, and
overproduction ROS (Furukawa et al., 2004; Tangvarasittichai,
2015). Moreover, NADPH oxidase is involved in fatty acids—
ROS generation in adipocytes once the treatment with NADPH
oxidase inhibitor blocks the ROS generation (Furukawa et al.,
2004; Tangvarasittichai, 2015).
Like oxidative stress, inflammatory state is also an important
feature of MS. Inflammation is one the manifestations of
oxidative stress (Roebuck, 1999; Tangvarasittichai, 2015). Festa
et al. (2000) demonstrated that chronic subclinical inflammation
is a key feature of the MS and components of MS (dyslipidemia,
abdominal obesity, and hypertension) increase in parallel to the
increasing levels of plasma CRP in non-diabetic individuals. It
is possible that chronic inflammation triggers MS (Festa et al.,
2000), overnutrition, cytokine hypersecretion, insulin resistance,
and diabetes in predisposed individuals (Festa et al., 2000). Festa
et al. (2000) also suggested that the decrease in insulin sensitivity
may lead to increase in CRP expression by counteracting the
physiological effect of insulin on hepatic protein synthesis
(Campos and Baumann, 1992; Festa et al., 2000).
Although there are many studies focusing on oxidative
stress, inflammation and MS (Campos and Baumann, 1992;
Roebuck, 1999; Festa et al., 2000; Furukawa et al., 2004;
Tangvarasittichai, 2015), there is still no clear consensus about
the causal relationship among the triad oxidative stress—
inflammation—MS.
The Sympathetic Nervous System and the
Metabolic Syndrome
The sympathetic nervous system (SNS) is an arm of the
autonomic nervous systemwhich plays vital role in the regulatory
mechanisms of blood pressure, sodium balance and maintenance
of homeostatic state. The SNS is fundamental in the control
of daily energy expenditure through the regulation of resting
metabolic rate and thermogenesis in response to physiological
stimuli, changing energy states, food intake, carbohydrate
consumption and hyperinsulinemia (Thorp and Schlaich, 2015).
Furthermore, the activation of sympathetic nerves in target
organs like liver, pancreas, skeletal muscle, and adipose tissue can
elicit acute catabolic responses (i.e., glycogenolysis and lipolysis)
(Thorp and Schlaich, 2015).
Over activation of SNS is strongly associated with two
components of the MS, i.e., obesity and hypertension
(Tentolouris et al., 2006). In fact, enhanced SNS activation
exerts unfavorable effects like cardiac hypertrophy, arterial
remodeling, and endothelial dysfunction on the cardiovascular
system (Grassi and Seravalle, 2006). Increase in sympathetic
activity enhances systemic and regional norepinephrine spillover
and elevate resting heart rate. This condition has been linked
to hypertension, obesity, and insulin resistance (Mancia et al.,
2007). Furthermore, it has been shown that high levels of fasting
insulin, an index of insulin resistance, were positively associated
with the low-to-high frequency (LF/HF) ratio of the heart rate
variability (HRV)—an index of the sympathovagal balance at the
heart level (Emdin et al., 2001).
In view of the strong relationship among obesity, MS and
the development of cardiovascular risk factors, it is important to
elucidate autonomic disturbances that occur in obese individuals.
As cited by Hall et al. (2000), there are two lines of evidences
about the central nervous system involvement in obesity-induced
hypertension: (i) increase in sympathetic activity in obese as
compared to lean subjects; and (ii) attenuation of obesity-related
hypertension through pharmacological blockade of adrenergic
activity (Landsberg and Krieger, 1989; Grassi et al., 1995;
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Hall et al., 2000). Though the autonomic disorders are not
homogeneous in obesity, some studies have demonstrated that
most individuals exhibit sympathetic hyperactivity (Lopes and
Egan, 2006). Both baroreflex sensitivity (BRS) and impaired
HRV in obese women (Skrapari et al., 2007). Esler et al. (2001)
demonstrated that the sympathetic tone in obese individuals
is increase in some target organs like kidney, skeletal muscle
and vessels. Sympathetic hyperactivity in obesity indicates that
obesity impairs renal-pressure natriuresis, increases renal tubular
sodium reabsorption and causes hypertension (Kassab et al.,
1995; Hall et al., 2000).
It is known that sympathetic disturbances are directly
related to increase in arterial blood pressure (Tan et al., 2010;
Oliveira-Sales et al., 2014). In humans, several features confirm
typical increase in sympathetic tone as observed in obesity.
Various studies have demonstrated increased blood pressure and
serum catecholamine levels in obese individuals. The loss of
weight is associated to the decrease in plasma concentration
norepinephrine (Tuck, 1992; Lopes and Egan, 2006). Obese
hypertensive children show increase in sympathetic nerve activity
(Rocchini et al., 1989; Lopes and Egan, 2006). However, in
these patients, a low salt diet (or hyposodic diet) is capable of
promoting a decrease in arterial pressure (Rocchini et al., 1989;
Lopes and Egan, 2006). These studies point out the fact that
sympathetic hyperactivity is related to sodium retention and
increase of arterial blood pressure in obese children (Lopes and
Egan, 2006). Furthermore, muscular sympathetic nerve activity
(MSNA) is increased in obese (normotensive and hypertensive)
as compared to non-obese normotensive individuals (Grassi
et al., 2000). Moreover, it has been shown that the MSNA and the
plasmatic norepinephrine are reduced and the BRS is increased
after weight loss in normotensive obese individuals (Grassi et al.,
1998; Lopes and Egan, 2006). The SNS response is blunted in
obese subjects despite the fact that plasma insulin levels were
almost 45% higher in the obese as compared to the lean patients
(Tentolouris et al., 2003).
The heart rate variations are a visible effect of the autonomic
influences on the heart in cases of emotional stress. An
inability to sustain varying heart rate is an important risk
factor to the development of CVD (Hemingway et al., 2001;
Brunner et al., 2002). The study of Brunner et al. (2002)
demonstrated a relative sympathetic dominance and a lower
vagal tone to the heart in MS cases, thereby indicating unbalance
sympathovagal in those individuals. Jamerson et al. (1993)
demonstrated an inverse relationship between sympathetic
vascular tone and the insulin-mediated cellular consumption
of glucose. Thus, it is not surprising to speculate that the
increased SNA as observed in obese individuals increases the
vascular constriction and impairs the glucose transportation into
the cells (Grassi et al., 2000; Lopes and Egan, 2006). Previous
studies with obese models have implicated vascular constriction
in insulin-resistance (Laakso et al., 1990; Lopes and Egan, 2006).
Specific alpha-adrenergic vasoconstriction seems to be more
malefic on glucose consumption than the angiotensin-induced
vasoconstriction (Jamerson et al., 1993; Lopes and Egan, 2006).
This assumption suggests, once again, sympathetic influence on
glucose metabolism.
In patients with type 2 diabetes mellitus (T2DM), MS has
approximately 70% of prevalence rate (Monami et al., 2007;
Bianchi et al., 2008). The basic mechanism involved in the
pathogenesis of T2DM is the insulin resistance. The insulin
resistance, in turn, is strongly associated with sympathovagal
imbalance. Furthermore, many data suggest the involvement
of increased SNS activity in insulin resistance (Mancia et al.,
2007). Epidemiological studies have found a correlation between
insulin resistance and hypertension (Modan and Halkin, 1991;
Skyler et al., 1995). In patients with type 1 diabetes mellitus
(T1DM), the hypertension is usually developed after the onset
of nephropathy and it is associated with rennin-angiotensin
induced SNS activation (Perin et al., 2001). In contrary, the
prevalence of hypertension in patients with T2DM is extremely
common (Perin et al., 2001). Thus, it can be assumed that Insulin
resistance and hypertension as observed in the MS are closely
linked with sympathetic overactivation (Frontoni et al., 2005).
The SNS activity plays a crucial role in the regulation
of circulation and blood pressure (Fisher and Paton, 2011;
Zubcevic et al., 2011). Sympathetic vasomotor and cardiac
neural activities are induced by the sympathetic preganglionic
neurons in the spinal cord. These neurons receive tonic excitatory
drive from pre-sympathetic networks within the brainstem and
hypothalamus (Dampney, 1994; Guyenet et al., 1996; Dampney
et al., 2002; Madden and Sved, 2003). Increased in SNS activity
has been linked to the pathogenesis of hypertension in humans
with essential hypertension (Abboud, 1984; Mancia et al., 1999;
Esler et al., 2001; Guyenet, 2006). Sympathetic overload is
implicated in the pathogenesis and/or deterioration of essential
hypertension through the modification of heart rate, cardiac
output, peripheral vascular resistance and renal sodium retention
(Grassi and Seravalle, 2006). The study of sympathetic nerve
firing rate in hypertensive patients has shown sympathetic
overactivity in young, middle-aged, and elderly hypertensive
(Grassi et al., 2000). Some studies with essential hypertensive
patients have plasmatic overflow of norepinephrine. This
overflow indicates an increase in the activation of sympathetic
outflow to the heart, kidneys and cerebrovascular circulation of
these individuals (Esler et al., 1991; Mancia et al., 2007). These
observations are evidences that some target organs are negatively
affected by increased blood pressure (Grassi et al., 2007).
Moreover, increase in heart rate has been observed in subjects
with MS as compared to those without MS (Mancia et al., 2007).
In this way, the physical inactivity can be associated with obesity
as well as to the increase in cardiac sympathetic drive in the MS.
The SNS disturbances are closely related to all the main
features of the MS. Although SNS participation in the
pathophysiology of MS is clear, it is difficult to determine
whether the metabolic changes are responsible for sympathetic
disturbances or vice versa.
Role of Leptin in the Elevation of
Sympathetic Activity
Obesity, an important risk factor for the development of MS, is
characterized by the increase in size and number of adipocytes
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(cells that produce adipokines, Martínez-Martínez et al., 2014).
Leptin is one of the adipokines that has been postulated as a link
between obesity and cardiovascular damage (Martínez-Martínez
et al., 2014). Leptin is a peptide synthesized and secreted from
white adipose tissue (Head et al., 2014) in addition to other
sources like placenta, stomach, and heart (Zeidan et al., 2011).
Leptin expression can be induced by obesity, insulin and TNF-
α. This adipokine has been implicated in numerous physiological
functions such as immune response and reproduction (Frühbeck,
2002; Mark, 2013). However, its main action is related to glucose
homeostasis and regulation of appetite. This hormone provides
feedback to the CNS on the status of peripheral energy reserves
(Rahmouni, 2010).
Plasma leptin concentrations are significantly elevated in
several rodent and human models of obesity in a proportional
manner to adiposity (Magni et al., 2000). Although circulating
levels of leptin rise in obesity, these individuals are thought to
be leptin resistant due to lack of satiation (Magni et al., 2000).
It is known that systemic infusion of leptin increased renal
sympathetic nerve activity (RSNA) and supplies (Haynes et al.,
1997). Central infusion of this peptide increases blood pressure
(Shek et al., 1998). Head et al. (2014) recently demonstrated that
central infusion of leptin antagonist in obese rabbits is able to
return blood pressure to their basal levels (Head et al., 2014).
These findings may contribute to understand an obesity-induced
hypertension. Furthermore, recent studies have demonstrated
that antagonism of central leptin receptor, LepR, caused a
reduction in BP and HR in hypertensive mice (Tumer et al.,
2007). The cardiovascular effects of leptin administration are not
exclusively due to its central action. In fact, it has been shown that
systemically administration of leptin antibodies elicited similar
changes as compared to central administration (Tumer et al.,
2007).
In an animal model of non-obese animals with
hyperleptinemia, leptin increased systolic blood pressure and
promoted an increase in intrarenal and systemic oxidative stress
(Beltowski et al., 2004). In these model, the increase in ROS cause
inactivation of nitric oxide. This effect can explain the leptin-
associated hypertension in this model (Beltowski et al., 2004;
Martínez-Martínez et al., 2014). Renal sodium retention has
also been implicated in hyperleptinemia hypertension (Martin
et al., 2008). Beltowski et al. (2004) have demonstrated that
hyperleptinemia decreases urinary sodium excretion to promote
volume retention and consequent increase in arterial blood
pressure. Other harmful effects such as atherosclerosis (Gruen
et al., 2007), inflammation, thrombosis and cardiac myocyte
hypertrophy (Northcott et al., 2012) have been associated
with leptin. Based on these observations, it is reasonable to
suggest that pharmacological approaches targeting leptin’s effects
could represent a potentially useful therapeutic strategy for
the treatment of obesity-associated hypertension among other
cardiovascular disease.
Treatment of Metabolic Syndrome
Since MS is a clustering of dysfunctions, different treatment
strategy has been adopted. WHO suggested treatments focusing
on insulin resistance as first-line therapy. A more active lifestyle
(which could lead to the weight loss) could be a promising
therapy as it decreases insulin resistance. Since there are direct
relationships between sedentary lifestyle and cardiovascular
risk factors, the benefits of physical exercises on the prognosis
of the MS are clear (Lakka et al., 2003; Rennie et al., 2003).
In fact, translational studies demonstrate lower insulin levels
and increased insulin sensitivity in athletes as compared to
match-aged sedentary individuals (Nuutila et al., 1994; Roberts
et al., 2013). Eriksson et al. (1997) demonstrated that one
single session of exercise increase the glucose offer mediated by
insulin in healthy and insulin resistant obese and type 2 diabetes
individuals. Chronic exercise improves insulin sensibility in
healthy, non-diabetic obese, type 1 and 2 diabetic individuals
(Eriksson et al., 1997). Also, the use of drugs like metformin and
thiazolidinediones (insulin sensitizers) have also been prescribed
for insulin resistance treatment (Einhorn et al., 2003; Grundy
et al., 2004).
As previously mentioned, the serum phosphate and
magnesium is reduced in MS patients (Stoian and Stoica,
2014). The compensatory hyperinsulinemia can promote
decrease of serum phosphate and magnesium, a vicious cycle
which contributes to the pathophysiology of MS (Stoian and
Stoica, 2014). Hence, a pharmacological treatment that restores
the level of these ions could be beneficial (Stoian and Stoica,
2014) to MS patients.
Final Considerations
The definition and diagnostic criteria of MS are still controversial
for obvious reasons. The divergent opinions on the diagnosis
of MS among health institutions constitute challenges to its
treatment and identification of individuals at high risk of CVD
and diabetes. The diagram presented in the Figure 1 below
summarizes the complex relationship between some of the MS
components.
A clinical diagnosis of MS is critical as it affects therapeutic
strategy. A multidisciplinary approach including lifestyle
changes, pharmacological and surgical approaches could be
helpful toward the management of this syndrome. Physical
inactivity, insulin resistance, advance age, hormonal factors
(androgens and corticosteroids), and diets rich in fats
which promote abdominal obesity or adiposity have been
consistently identified as major risk factors of MS. Atherogenic
dyslipidemia, elevated blood pressure, smoking, elevated glucose,
prothrombotic, and proinflammatory state are cardiovascular
risk factors that accompany MS. Change in lifestyle and anti-
obesity drugs among others could engender effective prevention
or treatment of MS. Although, lifestyle changes remain first-line
therapy for the improvement of all the underlying metabolic
risk factors, cases of unsuccessful lifestyle modification therapy
can be substituted with anti-obesity treatment. Lifestyle therapy
could dampen MS progression at every stage. This kind of
therapy does not treat each risk factor in isolation but rather
target multiple risk factors simultaneously. Although lifestyle
therapy may not modify any given risk factor as much as drug,
its benefit lies in the fact that it produces moderate reduction
in all metabolic risk factors. In most situations, drug therapies
might be required in the case of worsening condition of MS.
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FIGURE 1 | Hypothetical diagram summarizing the relationship between the components of the metabolic syndrome.
The effectiveness of drugs targeting individual risk components
of MS separately is still uncertain. This approach could lead
to aggressive use of medications at the expense of lifestyle
therapy. The ineffectiveness of some available drugs for the
treatment of MS has been compounded by the impractical
approach of simultaneous prescription and administration
of all the drugs that could modify all of the risk factors.
Current efforts being made to combine drugs into a single
capsule that targets multiple risk factors seems ingenious as
it could reduce the burden of polypharmacy. A single drug
that can affect multiple metabolic risk factors simultaneously
and provide health benefit to MS patient seems promising.
Drugs that act as angiotensin and adrenergic (alpha and beta)
receptors blockers and peroxisome proliferator–activator
receptor-γ agonism could lower blood pressure, vascular
and cardiac sympathetic tone as well as plasmatic glucose
simultaneously. Though new drug development programme
looks interesting, better understanding of MS, improved
diagnostic criteria and treatment strategy is key to future clinical
practice.
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